本研究旨在探讨308nm准分子激光(308nmEL)和他克莫司软膏(TO)治疗面部白癜风(FV)的疗效和安全性。我们搜索了科克伦图书馆,pubmed,EMBASE,CNKI,和万丰自成立至2023年6月1日。结果包括总体反应率(ORR),总不良反应率(TARR),3个月复发率(RR-3)和6个月复发率(RR-6)。结果数据以比值比(OR)和95%置信区间(CI)表示。通过Cochrane偏差风险工具评估偏差风险,并通过RevMan5.4软件进行数据分析。这项研究共纳入19项试验,涉及2085名患者。当比较308nmEL单药治疗与308nmEL加TO时,ORR的显著差异(OR=4.29,95%CI[2.97,6.19],I2=0%,P<0.001),RR-3(OR=0.18,95%CI[0.05,0.69],I2=0%,P=0.01),和RR-6(OR=0.38,95%CI[0.14,1.03],I2=39%,在两个管理之间发现P=0.06)。比较TO单药治疗与TO加308nmEL时,结果显示ORR存在显著差异(OR=4.21,95%CI[2.90,6.11],I2=0%,P<0.001),TARR(OR=0.42,95%CI[0.22,0.81],I2=4%,P=0.009),和RR-3(OR=0.32,95%CI[0.01,8.03],两种模式之间的P=0.49)。该研究的结果表明,对于FV的治疗,308nmEL和TO的组合比单独的任一治疗更有效。
This study aimed to investigate the effects and safety of 308 nm excimer laser (308 nm EL) and tacrolimus ointment (TO) in the treatment of facial vitiligo (FV). We searched Cochrane Library, PUBMED, EMBASE, CNKI, and WANGFANG from inception to June 1, 2023. Outcomes included overall response rate (ORR), total adverse reaction rate (TARR), recurrence rate at 3-month (RR-3) and recurrence rate at 6-month (RR-6). The outcome data were presented as odds ratios (OR) with 95% confidence intervals (CI). The risk of bias was assessed by Cochrane risk-of-bias tool and data analysis was performed by RevMan 5.4 software. This study included a total of 19 trials involving 2085 patients. When comparing 308 nm EL monotherapy with 308 nm EL plus TO, significant differences in the ORR (OR = 4.29, 95% CI [2.97, 6.19], I2 = 0%, P < 0.001), RR-3 (OR = 0.18, 95% CI [0.05, 0.69], I2 = 0%, P = 0.01), and RR-6 (OR = 0.38, 95% CI [0.14, 1.03], I2 = 39%, P = 0.06) were found between the two managements. When comparing TO monotherapy with TO plus 308 nm EL, its results showed significant differences in the ORR (OR = 4.21, 95% CI [2.90, 6.11], I2 = 0%, P < 0.001), TARR (OR = 0.42, 95% CI [0.22, 0.81], I2 = 4%, P = 0.009), and RR-3 (OR = 0.32, 95% CI [0.01, 8.03], P = 0.49) between the two modalities. The results of this study suggest that the combination of 308 nm EL and TO is more effective than either treatment alone for the treatment of FV.